Identification of divergent PTPN11 mutations in canine histiocytic sarcomas reveals evidence of an independent clonal origin
Abstract
BACKGROUND: Histiocytic sarcoma (HS) is a rare but highly aggressive neoplasm in humans, with limited knowledge on indicators markers and no standardized treatment. Dogs naturally develop HS, offering a powerful comparative model. Activating mutations in PTPN11, affecting two recurrent hotspots (E76 and G503), are the most frequent drivers of canine HS and are strongly associated with the disseminated form (DHS). While DHS is typically considered metastatic, we hypothesize that multiple independent tumor clones may arise within the same individual. METHODS: We investigated clonal heterogeneity in 38 dogs affected with DHS presenting tumors in both abdominal and thoracic organs. PTPN11 hotspot mutations were analyzed by high-sensitivity droplet digital PCR (ddPCR) to detect low-abundance variants. The frequency of divergent mutations between tumor sites was used to infer the proportion of cases arising from independent clonal origins. RESULTS: Divergent PTPN11 mutations were directly observed in 3 of 28 dogs with PTPN11-mutated tumor pairs. After correcting for the limited detectability inherent to hotspot-based analysis, we estimated that, in this cohort, up to 24-45% of DHS cases may harbor clonally independent PTPN11 mutations in distinct tumors. In addition, analysis of somatic mutations and copy number variants by Next Generation Sequencing (NGS) in two cell lines derived from the same patient confirmed the independent origin of the clones. CONCLUSIONS: Our findings suggest that a significant numbers of dogs with DHS develop several genetically distinct HS lesions either simultaneously or within a short time interval. This need to be confirmed in larger cohorts but this clonal diversity challenges the assumption that DHS is predominantly metastatic and has major implications for prognosis, therapeutic strategies, and the use of canine HS as a comparative model for human disease. Further exploration of clonal evolution in HS is warranted to improve treatment approaches in both species.
Related
- Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
- GeneFamHunter: annotation-independent recovery of divergent and tandemly arrayed gene-family members from genome assemblies
- Legacy of Recurrent Gene Flow and Evidence of Independent Evolution of ALS Resistance Mutations in Weedy Rice.
- Identification of Potential Biomarkers for Ulcerative Colitis and Analysis of Immune Cell Infiltration: A Study Based on Data-Independent Acquisition Proteomics and the GEO Public Database.
- MOCHI enables systematic identification of candidate independent intronic transcriptional signals from short-read RNA-seq data
BibTeX
@article{mottier2026identification,
title = {{Identification of divergent PTPN11 mutations in canine histiocytic sarcomas reveals evidence of an independent clonal origin}},
author = {Stéphanie Mottier and Armel Houel and Solveig Bouchard and Charline Bianchi and Louis Le Nézet and Richard Guyon and Stéphane Dreano and Thomas Derrien and Jérôme Abadie and Catherine André and Benoit Hédan},
journal = {PLoS ONE},
year = {2026},
month = sep,
doi = {10.1371/journal.pone.0345429},
url = {https://hal.science/hal-05746888v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Identification of divergent PTPN11 mutations in canine histiocytic sarcomas reveals evidence of an independent clonal origin
AU - Stéphanie Mottier
AU - Armel Houel
AU - Solveig Bouchard
AU - Charline Bianchi
AU - Louis Le Nézet
AU - Richard Guyon
AU - Stéphane Dreano
AU - Thomas Derrien
AU - Jérôme Abadie
AU - Catherine André
AU - Benoit Hédan
PY - 2026
DA - 2026/09/11
JO - PLoS ONE
DO - 10.1371/journal.pone.0345429
UR - https://hal.science/hal-05746888v1
AB - BACKGROUND: Histiocytic sarcoma (HS) is a rare but highly aggressive neoplasm in humans, with limited knowledge on indicators markers and no standardized treatment. Dogs naturally develop HS, offering a powerful comparative model. Activating mutations in PTPN11, affecting two recurrent hotspots (E76 and G503), are the most frequent drivers of canine HS and are strongly associated with the disseminated form (DHS). While DHS is typically considered metastatic, we hypothesize that multiple independent tumor clones may arise within the same individual. METHODS: We investigated clonal heterogeneity in 38 dogs affected with DHS presenting tumors in both abdominal and thoracic organs. PTPN11 hotspot mutations were analyzed by high-sensitivity droplet digital PCR (ddPCR) to detect low-abundance variants. The frequency of divergent mutations between tumor sites was used to infer the proportion of cases arising from independent clonal origins. RESULTS: Divergent PTPN11 mutations were directly observed in 3 of 28 dogs with PTPN11-mutated tumor pairs. After correcting for the limited detectability inherent to hotspot-based analysis, we estimated that, in this cohort, up to 24-45% of DHS cases may harbor clonally independent PTPN11 mutations in distinct tumors. In addition, analysis of somatic mutations and copy number variants by Next Generation Sequencing (NGS) in two cell lines derived from the same patient confirmed the independent origin of the clones. CONCLUSIONS: Our findings suggest that a significant numbers of dogs with DHS develop several genetically distinct HS lesions either simultaneously or within a short time interval. This need to be confirmed in larger cohorts but this clonal diversity challenges the assumption that DHS is predominantly metastatic and has major implications for prognosis, therapeutic strategies, and the use of canine HS as a comparative model for human disease. Further exploration of clonal evolution in HS is warranted to improve treatment approaches in both species.
SN - 1932-6203
SN - 1932-6203
ER -